SunTrust analyst Peter Lawson says that at first glance, AstraZeneca's (AZN) data in ovarian cancer maintenance setting with Lynparza looks "far better than expected." Lynparza showed "robust" median progression-free survival of 19.1 months and an "exceptionally high" 30.2 months when independently reviewed, versus 5.5 months with placebo control, Lawson tells investors in a research note. Even if the 30.2 month survival is discounted pending more detail, the data close the gap on TESARO (TSRO), the analyst contends. He believes, however, that TESARO's niraparib still has the advantage of a potentially broader label of platinum sensitive patients. Lawson keeps a Buy rating on TESARO with a $221 price target. The stock closed the trading day down 11% to $153.65.

Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).